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SUMMARY
The inflammasomes control the bioactivity of pro-inflammatory cytokines of the interleukin (IL)-1 family. The
inflammasome assembled by NLRP3 has been predominantly studied in homogeneous cell populations
in vitro, neglecting the influence of cellular interactions that occur in vivo. Here, we show that platelets boost
the inflammasome capacity of human macrophages and neutrophils and are critical for IL-1 production by
monocytes. Platelets licenseNLRP3 transcription, thereby enhancing ASC oligomerization, caspase-1 activ-
ity, and IL-1b secretion. Platelets influence IL-1b production in vivo, and blood platelet counts correlate with
plasmatic IL-1b levels in malaria. Furthermore, we reveal an enriched platelet gene signature among the high-
est-expressed transcripts in IL-1b-driven autoinflammatory diseases. The platelet effect is independent of
cell-to-cell contact, platelet-derived lipid mediators, purines, nucleic acids, and a host of platelet cytokines,
and it involves the triggering of calcium-sensing receptors on macrophages. Hence, platelets provide an
additional layer of regulation of inflammasomes and IL-1-driven inflammation.
INTRODUCTION
An unbalanced production of interleukin-1 (IL-1) cytokines drives
the immunopathology of several auto-inflammatory diseases
(Sims andSmith, 2010). As nearly all cells express the IL-1 recep-
tor (IL-1R), IL-1 cytokines have the ability to influence innate and
adaptive immunity and exert broad effects in the body. IL-1b is
unique in the medical literature: while many human inflammatory
diseases are caused by a host of cooperative inflammatory fac-
tors, mutations in genes controlling the expression of IL-1b
cause a spectrum of life-threatening auto-inflammatory syn-
dromes (Broderick et al., 2015). Monotherapies blocking IL-1b
activity in patients with auto-inflammatory syndromes result in
a rapid and sustained reversal of symptoms and severity (Dinar-
ello et al., 2012) and are currently the first line of intervention
against these conditions. A growing bulk of evidence has now
characterized other common inflammatory andmetabolic condi-
tions as responsive to IL-1b neutralization (Dinarello, 2011; Di-
narello and van der Meer, 2013). This was further validated by
the results of the CANTOS Study, which showed that canakinu-
mab, a humanized anti-IL-1b monoclonal antibody, significantly
reduced the risk for recurrent cardiovascular events (Ridker
et al., 2017a) and indicated that IL-1b is associated with
increased incidence of fatal lung cancer (Ridker et al., 2017b).
The expression of IL-1 cytokines is tightly regulated. For
instance, the production of some members of this family (e.g.,
IL-1b and IL-18) is restricted to immune cells. Furthermore,
upon induction, these proteins are synthesized as inactive pre-
cursors in the cytosol, and a series of intracellular events is
required for their maturation and release into the extracellular
space. These events include the assembly of inflamma-
somes—intracellular protein complexes formed by a sensor—
such as NLRP3, the adaptor protein apoptosis-associated
speck-like protein containing a CARD (ASC), and the cysteine
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protease caspase-1 (Latz et al., 2013). Upon activation, inflam-
masome sensors recruit ASC, which oligomerizes to form a
micron-sized structure termed ASC speck, which recruits and
activates caspase-1. Active caspase-1 processes pro-IL-1b
and pro-IL-18 into their bioactive forms and drives an inflamma-
tory cell death, termed pyroptosis, through gasdermin-D-
induced membrane pore formation and leakage of cytosolic
content (Kayagaki et al., 2015; Liu et al., 2016).
Themajority of the studies on inflammasomeswere performed
in vitro, predominantly in monocultures of macrophages.
Although this approach allowed the discovery of molecular
mechanisms controlling inflammasomes, it underestimated the
influence of other cell populations on the regulation of IL-1 cyto-
kines in vivo. For instance, it has been recently discovered that
T cells drive inflammasome-independent IL-1b production by
dendritic cells (DCs) (Jain et al., 2020).
Around one trillion platelets (150–450 3 109/L) circulate in the
blood of a healthy individual, outnumbering all other leukocytes
in the vasculature by several folds. Platelets have been increas-
ingly recognized for their roles in immunity (Carestia et al., 2019;
Dann et al., 2018; Kral et al., 2016; Passacquale et al., 2011) and
were reported to produce IL-1 cytokines (Allam et al., 2017; De-
nis et al., 2005; Hawrylowicz et al., 1989; Thornton et al., 2010).
More recently, they were reported to assemble inflammasomes
(Cornelius et al., 2019; Hottz et al., 2013). Platelets could there-
fore be relevant cellular sources of IL-1 or extracellular ASC
specks in vivo or could alter the inflammatory responses of other
immune cells.
Here, we report that platelets are essential for the full inflam-
masome activation of innate immune cells. Co-culture with
platelets not only boosted the NLRP3 activation and production
of IL-1a, IL-1b, and IL-18 from human macrophages and neu-
trophils, but it was also crucial for the optimal production of
IL-1 cytokines by human monocytes. Platelets specifically influ-
enced the NLRP3 inflammasome activation of macrophages in
trans by enhancing the transcription of NLRP3 and IL-1b. Using
a series of complementary techniques that included assays
with human platelets and megakaryocytes (MKs), as well as
platelets and cells from knockout and transgenic mice, we
demonstrated that platelets and MKs do not express the com-
ponents of the canonical inflammasome (NLRP3, ASC, cas-
pase-1, and IL-1b). Indeed, the effect of platelets on human
monocyte-derived macrophages (hMDMs) was independent
of IL-1 signaling and did not require direct cell contact,
platelet-derived nucleic acids, lipid mediators, or purines, but
it could be neutralized by heat inactivation. We further show
that platelet depletion attenuated systemic production of IL-
1b in vivo. Furthermore, platelet counts and plasma levels of
IL-1b were positively correlated in naturally infected malaria pa-
tients. Moreover, we observed an enriched platelet signature
among the highest-expressed genes in a cohort of pediatric
patients with gain-of-function mutations in NLRP3 that cause
Muckle-Wells syndrome (MWS) and neonatal-onset multi-
system inflammatory disease (NOMID).
In summary, platelets fuel NLRP3 activity of immune cells and
shape IL-1 inflammation. Thus, platelet-modifying therapies
could have widespread implications for autoinflammatory and
autoimmune diseases.
RESULTS
Platelets Boost IL-1 Production in Inflammasome-
Activated Immune Cells
The NLRP3 inflammasome is primarily assembled in myeloid
cells. Although activated platelets are known to form aggregates
with and modulate the functions of immune cells (Allen et al.,
2019; Carestia et al., 2019; Dann et al., 2018; Kral et al., 2016;
Passacquale et al., 2011), their effects on the inflammasome
activation of leukocytes remains unexplored. To address this
question, we investigated the influence of platelets on the pro-
duction of IL-1 cytokines elicited by the bona fide NLRP3 inflam-
masome activators Nigericin and ATP in mouse and human
immune cells. Mouse bone marrow-derived macrophages
(BMDMs) (Figure 1A), hMDMs (Figure 1B), human neutrophils
(Figure 1C), and human CD14+ monocytes (Figure 1D) were
cultured or not with platelets. Co-cultures were left untreated
or primed with lipopolysaccharide (LPS), followed by NLRP3
activation. The levels of IL-1b and tumor necrosis factor alpha
(TNF-a) were measured in cell-free supernatants. A multiplex
cytokine assay was used to additionally measure the production
of IL-1a and IL-18, two other members of the IL-1 family, along
with several other cytokines and growth factors in hMDMs and
human neutrophils (Figures S1A and S1B). Co-culture with plate-
lets boosted the production of IL-1b from mouse and human in-
flammasome-activated macrophages and human neutrophils
(Figures 1A–1C) without significantly altering the release of
lactate dehydrogenase (LDH) from activated cells (Figure S2A).
Fitting a sigmoidal curve between the IL-1b levels produced in in-
flammasome-activated macrophages and the platelet-macro-
phage ratio, we found a strong (R = 0.8886, p = 0.0163) concen-
tration-dependent effect of platelets in these cells (Figure S1C).
The addition of platelets also boosted the release of IL-18 and
IL-1a from activated hMDMs (Figure S1A). Extending these re-
sults, the addition of platelets to neutrophils also enhanced their
production of IL-8 (Figure S1B). Platelets alone produced CCL5
(RANTES) and low levels of IL-18 that were close to the detection
limit of the assays. Platelets lacked expression of most of the
other investigated cytokines (Figures 1, S1A, and S1B), indi-
cating that they do not directly contribute to the cytokines
measured in the co-cultures. Notably, the co-culture of platelets
with mouse macrophages, human monocytes, and neutrophils,
but not hMDMs, resulted in diminished TNF-a production in
response to LPS stimulation. These results suggest that despite
NFkB being a common transcription factor regulating the pro-
duction of TNF-a and IL-1 cytokines, platelets differentially regu-
late the production of these cytokines.
Next, we asked whether platelets also influence the activity of
other inflammasomes. For this, we activated AIM2 or NLRC4,
respectively, by intracellular delivery of double-stranded DNA
(dsDNA) (Poly[dA:dT]) (Figure S1D) or the rod protein of the
T3SS apparatus from Salmonella typhimurium (PrgI) (STAR
Methods; Figure S1E) in co-cultures of human platelets and
macrophages. Stimulation of the AIM2 or NLRC4 inflamma-
somes in hMDMs resulted in IL-1b secretion, which was not
significantly altered by the addition of platelets (Figures S1D
and S1E), indicating that the platelet effect was NLRP3-specific.
Co-culture with platelets also boosted IL-1b production from
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hMDMs primed with Toll-like receptor (TLR)2 or TLR7/8 agonists
(Pam3Csk4 and R848, respectively) (Figure S1F), indicating that
the platelet effect is not exclusively mediated through TLR4.
However, blockade of TLR4 signaling on hMDMs with resatorvid
(TAK-242) (Matsunaga et al., 2011) partially prevented the effect
of platelets (Figure S1G), indicating that the platelet effect is in
part orchestrated by TLR4. Together, these data show that
platelets boost the production of IL-1 cytokines in NLRP3-acti-
vated innate immune cells.
Platelets AreCritical for the InflammasomeActivation of
Human Monocytes
Notably, co-culture with platelets did not influence the produc-
tion of IL-1b by inflammasome-activated monocytes (Figure 1D),
likely due to the steady-state presence of contaminating plate-
lets on the preparations of freshly isolated monocytes. To
address that, we isolated CD14+ monocytes from peripheral
blood using magnetic separation kits, added or not with a
platelet removal cocktail (STAR Methods). Cell purity was as-
sessed by fluorescence-activated cell sorting (FACS) (Figure 2A).
Platelet depletion efficiently reduced the numbers of free plate-
lets (CD41+CD14–) or platelets associated with monocytes
(CD41+CD14+), while enriching the frequency of platelet-free
monocytes (CD14+CD41–) (Figures 2A and 2B). Importantly,
platelet depletion was not detrimental to monocytes, assessed
by LDH release (Figure S2B). However, platelet removal impaired
the cytokine response of NLRP3-activated monocytes. Notably,
monocyte responses could be restored by the re-addition of
autologous platelets (Figures 2C and S2C). These data indicate
that platelets are crucial for monocytes to trigger an optimal in-
flammatory response.
Human monocytes can also engage an alternative inflamma-
some activation, in which LPS alone is sufficient to trigger IL-
1bmaturation and secretion (Gaidt et al., 2016). To test the effect
of platelet removal in alternatively activatedmonocytes, we stim-
ulated standard or platelet-depleted CD14+monocytes with LPS
(1 mgmL1) for 16 h. Similar to the effect on the canonical inflam-
masome (Figure 2C), platelet depletion impaired the IL-1b
response from alternatively activated cells (Figure 2D), and the
re-addition of platelets rescued their IL-1b production
(Figure 2D).
Next, we asked whether co-culture with platelets could also
enhance NLRP3 activation in the monocytic cell line THP-1,
which has been used extensively to characterize the biology of
the inflammasomes. As expected (Gaidt et al., 2016, 2017),
NLRP3-activated THP-1s were able to produce IL-1b on their
own. Nevertheless, co-culture with platelets boosted the pro-
duction of IL-1b by THP-1s to levels comparable to those pro-
duced by primary monocytes (Figure 2E). No IL-1bwas detected
on platelets cultivated alone. Together, these findings reveal that
platelets are critical for optimal inflammasome activation by hu-
man monocytes.
Platelets Influence IL-1 Responses In Vivo
As monocytes and macrophages are relevant sources of IL-1,
we reasoned that plateletsmight influence IL-1 responses in vivo.
Therefore, we investigated the effects of platelet depletion using
a mouse model of systemic IL-1-dependent inflammation
Figure 1. Platelets Boost Inflammasome Activation of Innate Immune Cells
(A–D) IL-1b and TNF-a levels released by unstimulated (Unstim), LPS-primed, and Nigericin, or ATP-activated (A)WTBMDMs, (B) humanmacrophages (hMDMs),
(C) neutrophils, or (D) monocytes. Cells were cultivated alone () or with platelets (+Plts) in the indicated ratios. Data is presented as floating bars (with mean and
minimum tomaximum values) and pooled from at least three independent experiments with cells and platelets from different donors. Each symbol represents the
average from technical triplicates per blood donor or mouse.
See also STAR Methods and Figure S1.
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triggered by imidazoquinolinone compounds (Kanneganti et al.,
2006). We induced thrombocytopenia in mice by intravenous
(i.v.) injection of a GPIba monoclonal antibody (aCD42b).
Treatment with aCD42b has been widely used in literature (Bar-
rett et al., 2019; Boilard et al., 2010; Sreeramkumar et al., 2014;
Xiang et al., 2013) and results in a drop of the blood platelet
counts (Figures 3A, S3A, and S3B), with no reported effects on
the blood counts of other leukocytes (Barrett et al., 2019; Pack-
ham et al., 2014). As previously reported (Kanneganti et al.,
2006), intraperitoneal (i.p.) injection of R848 in combination
with LPS induced robust IL-1b systemically, measured in sera
(Figure 3B), and locally, in peritoneal lavage (PEL) (Figure 3C).
Notably, this response was attenuated by platelet depletion.
Although levels of IL-1b were significantly lower in the sera of
platelet-depleted mice (Figure 3B), we could not detect IL-1b
in the PEL of all mice (Figure 3C). Importantly, platelet depletion
did not affect the migration of neutrophils and monocytes to the
peritoneum (Figures 3D and S3B). These data suggest that the
decrease in IL-1b levels was not due to reduced peritoneal
leukocyte counts.
Platelets were reported to amplify IL-1 inflammation in rheu-
matoid arthritis (RA) (Boilard et al., 2010) and more recently in
atherosclerosis (Barrett et al., 2019), two inflammatory diseases
characterized by strong IL-1 inflammation (Di Giovine et al.,
1987; Joosten et al., 2009; Mantovani et al., 2019; Ridker et al.,
2017a), supporting their role in modulating IL-1 levels in vivo. In
line with this hypothesis, a positive correlation between blood
platelet counts and plasma IL-1b concentrations was recently
reported in a cohort of 500 healthy, Caucasian volunteers (Netea
et al., 2016; Tunjungputri et al., 2018). However, blood leukocyte
counts were equally correlated with plasma levels of IL-1b in that
study, hindering the precise contribution of platelets for the IL-1b
concentrations (Tunjungputri et al., 2018). To investigate the
relation between platelet counts and IL-1b concentrations in
the context of disease, we studied a cohort of human subjects
naturally infectedwithPlasmodium vivax, the predominant cause
ofmalaria in the Brazilian Amazon (Howes et al., 2016). Infections
with P. vivax commonly cause pro-inflammatory cytokine imbal-
ance (Andrade et al., 2010), with thrombocytopenia and anemia
being the two most commonly associated complications. We
Figure 2. Platelets Are Critical for the Production of IL-1 Cytokines by Human Primary Monocytes
(A) Representative FACS dot plots of CD41 and CD14 expression in human PBMCs, standard (Std-Mo), or platelet-depleted (PD-Mo) CD14+ monocytes (see
STAR Methods).
(B) Quantification of platelets (CD41+CD14), platelet-monocyte aggregates (CD41+CD14+), and platelet-free monocytes (CD41CD14+) in PBMCs and isolated
monocytes.
(C) IL-1b and TNF-a levels in cell-free supernatants of Std-Mo versus PD-Mo, or in platelet-depleted monocytes replenished with autologous platelets (PD-Mo +
Plts, 50:1 Ptl:Cell), and stimulated as indicated.
(D and E) IL-1b levels released by non-canonically activated Std-Mo, PD-Mo, or PD-Mo + Plts, stimulated with LPS (1 mg mL1) for 16 h (D) or by inflammasome-
activated THP-1 s ± platelets (E). Data is presented as floating bars (with mean and minimum to maximum values) and pooled from independent experiments.
Each symbol represents the average from technical triplicates per blood donor. Data in (D) shows bar graph with Mean + SD, from a representative of two in-
dependent experiments.
See also Figure S2.
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found that platelet counts positively correlated with plasma IL-1b
concentrations (Spearman’s R = 0.504, p = 0.0028). Despite a
positive trend, no correlations were found between platelet
counts and IL-1a (R = 0.15, p = 0.37) or TNF-a (R = 0.014,
p = 0.917) (Figure 3E). Unexpectedly, IL-18 levels were nega-
tively correlated with platelet counts (R = 0.45, p < 0.0001),
which suggests that different mechanisms regulate the produc-
tion of this cytokine in vivo. Supporting this hypothesis, heme
(Li et al., 2014) and oxidized hemoglobin were shown to activate
the NLRP3 inflammasome (Nyakundi et al., 2019). Indeed, IL-18
(R = 0.32, p = 0.005) and TNF-a (R = 0.29, p = 0.003) corre-
lated with hemoglobin levels (Figure 3E), suggesting that anemia
may be a contributing factor for the regulation of these cytokines,
but not for the associations between platelet counts and IL-1b.
Importantly, none of the cytokines investigated correlated with
leukocyte counts (Figure 3E) in the malaria cohort. As leukocytes
are a relevant source in IL-1 cytokines in the blood, these data
support that platelets are major contributors in the regulation
of IL-1 levels in this context. IL-1b levels also had no correlation
with parasitemia (data not shown), suggesting that IL-1b produc-
tion may not be caused by Plasmodium-associated danger mol-
ecules (Dostert et al., 2009).
Next, we asked whether there is a relationship between plate-
lets and inflammation in exclusively IL-1b-driven human autoin-
flammatory syndromes (Broderick et al., 2015). We generated
a platelet gene signature comprising 45 transcripts known to
be either platelet-specific or strongly associated with platelet ac-
tivity from direct comparisons of publicly available gene expres-
sion analyses of purified human platelets (Eicher et al., 2016;
Rowley et al., 2011). Remarkably, 42 out of 45 platelet-signature
Figure 3. Platelets Influence IL-1 Levels In Vivo
(A) Representative FACS plots and quantification of platelets in the blood of mice treated with a platelet-depleting Ab (aCD42b) or IgG control.
(B and C) IL-1b levels in sera (B) or peritoneal lavage (C) from platelet-depleted mice after i.p. challenge with LPS + R848 (see STAR Methods).
(D) FACS quantification of neutrophils and monocytes in peritoneal lavage of mice treated as in (C).
(E) Correlation between plasma cytokines and blood cell counts or hemoglobin levels in naturally infectedmalaria patients (n = 78). Red lines, positive correlations;
shaded areas, 95% confidence; squared symbols, outliers (see STAR Methods).
(F) Volcano plot of log2 fold change versus significance (p value) highlighting the platelet-signature genes within transcripts of healthy (n = 14) versus pediatric
patients (n = 22) with NLRP3 mutations (NLRP3mut) causing MWS/NOMID (Balow et al., 2013).
See also Figure S3.
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genes were upregulated in the whole blood of pediatric patients
harboring NLRP3mutations (NLPR3mut) associated with the IL-
1-driven autoinflammatory disorders MWS and NOMID (Balow
et al., 2013; Goldbach-Mansky et al., 2006), compared to healthy
children (Figure 3F). Importantly, as reported in the original
cohort (Goldbach-Mansky et al., 2006), the baseline clinical
manifestations and blood cell counts of MWS/NOMID patients
were within the pediatric reference ranges, supporting that dif-
ferences in blood cell counts are likely not responsible for the
changes we observed. Collectively, these findings support that
platelets influence IL-1b in vivo.
Platelet Effect on Immune Cells Is Independent of
Platelet-Derived IL-1 or Platelet Inflammasomes
Previous reports have indicated that platelets express IL-1 cyto-
kines, including IL-1a (Thornton et al., 2010), IL-1b (Denis et al.,
2005), and IL-18 (Allam et al., 2017). However, as shown in Fig-
ures 1, S1A, andS1B, IL-1aand IL-1bwere not detected inmono-
cultures of platelets in our experimental settings. To exclude the
possibility that platelets directly contribute to the IL-1 cytokines
measured in our assays, we performed co-culture experiments
using platelets or BMDMs from mice with targeted genetic defi-
ciency in IL-1 proteins or IL-1 receptors. First, we activated the
NLRP3 inflammasome in wild-type (WT) BMDMs co-cultured
with platelets from either WT or IL-1b-deficient (Il1b–/–) mice.
We found that Il1b–/– platelets were equally able to boost IL-1b
production in inflammasome-activated BMDMs as WT platelets
(Figure 4A). Similarly, the addition of WT platelets to BMDMs
from IL-1R-deficient mice (Il1r–/–) also boosted their IL-1b pro-
duction upon inflammasome activation (Figure 4B), thus
excluding a role for platelet-derived IL-1a in mediating the
response. Finally, the addition of platelets to Il-18r–/– BMDMs
equally boosted their IL-1b production toward LPS + Nigericin
(Figure 4C), indicating that neither the platelet-derived IL-1a/b
nor the IL-18 cytokines could be responsible for the platelet
effect.
Recent studies reported the assembly of the NLRP3 inflamma-
some in platelets and their involvement in the pathogenesis of
dengue (Hottz et al., 2013) and sickle cell disease (Vogel et al.,
2018). To determine whether the co-activation of platelet
NLRP3 could contribute to the IL-1 production in co-cultures,
we tested if the addition of WT platelets could compensate for
the impaired IL-1 response of Nlrp3–/– or Pycard–/– (Asc–/–)
BMDMs. We stimulated LPS-primed Nlrp3–/– or Pycard–/–
BMDMs with Nigericin or ATP, alone or in co-culture with WT
platelets. As expected, macrophages from Nlrp3–/– and
Pycard–/– mice failed to produce IL-1b in response to inflamma-
some activation (Figure S2D). The addition of WT platelets to
Nlrp3–/– or Pycard–/– macrophages had no effect on the IL-1b
production by these BMDMs (Figure S2D), indicating that the
activation of inflammasomes in platelets is not involved in the
amplification of macrophage IL-1b responses. To determine
whether the NLRP3/ASC inflammasome is expressed and
assembled in platelets, we imaged inflammasome assembly in
bone marrow (BM) cells from transgenic (Tg) ASC-mCitrine
mice (Tzeng et al., 2016). ASC-mCitrine+ BM cells were stained
for leukocytes (CD45), neutrophils (Ly6G), and platelets (CD41)
and assessed by flow cytometry and confocal microscopy.
While ASCwas clearly visualized and assembled into fluorescent
specks in inflammasome-activated leukocytes (CD45+), macro-
phages (CD45+F4/80+), and neutrophils (CD45+Ly6G+), it was
not observed in platelets and MKs (CD41+cells) (Figures S3C
and S3D). These results were confirmed using flow cytometry
and confocal imaging of BM cells from ASC-mCherry knock-in
reporter mice (Figure S3E).
Most studies reporting the presence (Brown et al., 2013; Denis
et al., 2005) or activity (Hawrylowicz et al., 1989; Kaplanski et al.,
1993) of IL-1 cytokines or inflammasome molecules used prep-
arations of washed platelets without assessment of purity, which
could not rule out the presence of contaminating leukocytes in
their platelet preparations (Pillitteri et al., 2007). We therefore
re-evaluated the expression of the canonical inflammasome
components in platelets and peripheral blood mononuclear cells
(PBMCs) from healthy volunteers. The purity of platelet prepara-
tions was assessed by flow cytometry, microscopy, and qPCR
using platelet (PF4) and leukocyte markers (CD45, CD14) (Fig-
ures S4A–S4E and Table S1). Importantly, both freshly isolated
human and mouse platelets remained viable after purification
and upregulated P-selectin (CD62P) upon thrombin stimulation
(Figures S3F and S4E). Nevertheless, human platelets did not ex-
press the inflammasome components NLRP3, ASC, and cas-
pase-1, nor IL-1b at the mRNA (Figure S4D) and protein level
(Figures S4F–S4H), although thesemolecules were promptly de-
tected in PBMCs from the same donors and increased upon LPS
stimulation. Furthermore, unlike the human monocytic line
THP-1, no expression of IL-1b and inflammasome molecules
was detected in the human megakaryocytic cell MEG-01 (Fig-
ure S3G), which also failed to secrete mature IL-1b upon inflam-
masome activation (Figure S3H).
Finally, we re-analyzed publicly available transcription profiles
of purified platelets from five independent studies (Devignot
et al., 2010; Gnatenko et al., 2005; Londin et al., 2014; Raghava-
chari et al., 2007; Spivak et al., 2014), including the gene expres-
sion profiles of platelets from patients with dengue (Devignot
et al., 2010) and sickle cell disease (Raghavachari et al., 2007;
Figures S5A–S5E). In all these studies, we re-assessed the
expression of IL-1b and the inflammasome components
NLRP3, ASC, and caspase-1 using the expression of platelet
markers PF4 (CXCL4) or platelet-derived growth factor A
(PDGFA) as comparisons (Figures S5A–S5E). None of the
NLRP3, ASC, caspase-1, or IL-1b transcripts were detected in
human platelets in these studies (Figures S5A–S5E). Together
with our previous findings, these observations support the
conclusion that human and mouse platelets do not express the
components of the canonical NLRP3 inflammasome and are
therefore unable to assemble inflammasomes.
The Platelet Effect Is Mediated by a Soluble and
Constitutive Factor
Phagocytosis of activated platelets has been shown to regulate
platelet and neutrophil function, survival, and differentiation
(Badrnya et al., 2014; Chatterjee et al., 2015; Lang et al., 2002;
Senzel and Chang, 2013). To determine whether phagocytosis
is responsible for the effect of platelets on inflammasome activa-
tion, we performed confocal imaging of hMDMs (Figure 4D) and
purified blood neutrophils (Figure S2E) incubated with freshly
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Figure 4. The Effect Is Independent of Platelet-Derived IL-1 Cytokines or Inflammasomes
(A) IL-1b released by WT BMDMs ± platelets (5:1 ratio) from WT or Il1b–/– mice. Bar graph with Mean and SD from one experiment with three mice.
(B and C) IL-1b levels in cell-free supernatants of WT or Il1r–/– (B) or Il18r–/– (C) BMDMs ± platelets (5:1 ratio) from WT mice.
(D) IL-1b levels in cell-free supernatants of WT, Nlrp3–/–, or Pycard–/– BMDMs ±WT platelets (5:1 ratio). Confocal imaging of hMDMs co-cultured with platelets
(50:1 ratio). Cells were pretreated or not with Cytochalasin D before the addition of platelets. Blue (Draq5, nuclei); red (wheat germ agglutinin [WGA], plasma
membrane); green (anti-CD41, platelets).
(E) IL-1b released by hMDMs treated as in (D).
(F) Schematics of trans-well and IL-1b released by hMDMs cultured alone, in direct co-cultures with platelets (Well), or in trans-well (insert).
(G and H) IL-1b released by hMDMs ± platelets or platelet (G) and MK (H) supernatants. Graphs show floating bars (with mean and minimum to maximum values)
from pooled data from two to four independent experiments. Each symbol represents the average of technical triplicates from different donors.
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isolated platelets. Co-cultures were stimulated with LPS, fol-
lowed by inflammasome activation. Both hMDMs (Figure 4D)
and neutrophils (Figure S2E) phagocytosed platelets; however,
pretreatment of hMDMs with the phagocytosis inhibitor Cyto-
chalasin D did not prevent the platelet-mediated boost of IL-1b
(Figure 4E). Furthermore, platelets were able to boost the IL-1b
responses of hMDMs in both direct and in trans-well co-
cultures (Figure 4F), and cell-free supernatant from resting,
LPS-stimulated, or thrombin-activated platelets also enhanced
IL-1b production from hMDMs (Figure 4G). Importantly, thrombin
had no effect on macrophages stimulated in the absence of
platelets (Figure S2F). Thus, the platelet influence on IL-1b pro-
duction by inflammasome-activated macrophages is indepen-
dent of cell contact. In contrast, the transfer of platelet superna-
tants to cultures of human neutrophils or monocytes did not
promote a significant increase in the production of IL-1b (Fig-
ure S2G; data not shown), suggesting that cell-to-cell contact
may be required for the platelet-boosting effects in these cells.
We observed that supernatants from quiescent and activated
platelets had similar effects on the inflammasome activation of
hMDMs (Figure 4G). To determine whether this capacity of
quiescent platelets was due to undetectable activation during
isolation, we transferred supernatants from resting MEG-01 to
cultures of hMDMs. Similar to platelets, supernatants from
resting MEG-01 boosted the inflammasome activity in hMDMs
(Figure 4H). This finding points toward the presence of a soluble
and constitutively expressed factor secreted by both platelets
and MKs, which modulates the inflammasome activity of
macrophages.
Platelets License NLRP3 Transcription to Boost
Inflammasome Activation on Human Macrophages
In most immune cells, the activation of NLRP3 requires a priming
stimulus, such as the engagement of pattern recognition recep-
tors, that initiates the transcription of NLRP3. The amount of
NLRP3 available in the cytosol is a key limiting factor regulating
its activation. Sincewe observed that the platelet effect was spe-
cific to the activation of the NLRP3 inflammasome (Figures S1D
and S1E), we investigated if the platelet effect on macrophages
occurs at the transcriptional level during priming or afterward
during activation of the NLRP3 inflammasome. To this end, we
co-cultured NLRP3-overexpressing immortalizedmousemacro-
phages (NLRP3FiMøs) with platelets and directly stimulated
these cells with Nigericin. As the LPS priming signal is also
required for the upregulation of pro-IL-1b, we assessed cas-
pase-1 activity using a specific caspase-1 luminescence assay
as a readout. The addition of platelets to NLRP3FiMøs did not
enhance their caspase-1 activity (Figure 5A), supporting that
platelets influence the inflammasome activation of hMDMs by
enhancing the transcription of NLRP3. To determine whether
platelets modulate the expression of other inflammasome mole-
cules, we evaluated hMDMs cultivated or not with platelet super-
natants, whichwere used tominimize the detection of transcripts
arising from platelets. The addition of supernatants from resting
platelets to macrophages boosted their expression of IL-1b (Fig-
ure 5B and Table S1). Surprisingly, the platelet supernatant was
as effective as LPS to induce the expression of NLRP3 and pro-
IL-1b protein (Figure S2H, lanes 1 and 3). However, the platelet
supernatant did not alter the expression of pro-caspase-1 or
ASC (Figure 5B). In conformity with increased NLRP3 availability
in the cytosol, exposure to platelets boosted the formation of
ASC specks in hMDMs (Figure 5C). Importantly, cells stained
with isotype-matched immunoglobulin G (IgG), as well as plate-
lets cultured alone, did not show ASC specks (Figures 5C and
S6A). Co-culture with platelets or exposure to their supernatants
increased caspase-1 activation andmaturation of IL-1b in super-
natants of hMDMs (Figures 5D–5F). Again, these proteins were
not present in platelets (Figures 5D and 5E; Plts alone). We
also detected pro-IL-1b in cell-free supernatants of LPS-primed
hMDMs, likely due to cell death during LPS priming. Further-
more, despite lacking pro-IL-1b mRNA (Figure S4D) and protein
(Figures 5D, lane 11, and S4G), platelets and their supernatants
increased the concentrations of pro-IL-1b even on unstimulated
hMDMs (Figure 5D, lanes 3 and 4). Contrary to NLRP3, which re-
quires priming for its transcription, NLRC4 and AIM2 are consti-
tutively expressed in the cytosol of hMDMs, which might explain
why platelets had minor effects on the AIM2- or NLRC4-depen-
dent IL-1b secretion (Figures S1D and S1E). Altogether, these
findings indicate that platelets boost inflammasome activation
by enhancing the transcription of pro-IL-1b and NLRP3 in
hMDMs.
The Platelet-Mediated Amplification of Inflammasome
Activity RequiresCalciumandCanBePrevented byHeat
Inactivation
Platelets are sources of lipid mediators (Hinz et al., 2016) such as
prostaglandins (COX-1/2-derived mediators), which regulate
LPS-induced pro-IL-1b transcription (Zas1ona et al., 2017) and
inhibit TNF-a in macrophages (Chandra et al., 1995; Xiang
et al., 2013; Zas1ona et al., 2017). We therefore inhibited COX-
1/2 by pre-treating platelets with aspirin (Xiang et al., 2013).
Aspirin had no effect on platelet ability to boost IL-1b production
in hMDMs (Figure 6A). Similarly, pre-treatment of platelets with
Zileuton (Zt), an inhibitor of leukotriene synthesis, did not block
the platelet effect. Of note, aspirin and Zt had no effect on IL-
1b production when used directly on hMDMs (Figure 6A).
Activated platelets can also release nucleic acids and nucleo-
sides that display inflammatory properties (Qin et al., 2016).
However, degradation of free nucleic acids by Benzonase (Bz)
did not prevent the effect of platelet co-culture on IL-1b produc-
tion (Figure 6B). As platelets store other purines including ADP
and ATP, we added apyrase (Apy) to the co-culture of hMDMs
with platelets. Apyrase did not alter the effect of platelets on
the inflammasome activity of hMDMs (Figure 6C). Likewise, the
direct addition of extracellular ADP to inflammasome-activated
hMDMs also failed to recapitulate the platelet effect (Figure 6D).
This is in line with our findings that platelets boost macrophage
IL-1b production through transcriptional regulation during the
priming phase of inflammasome activation (Figures 5A and
5B). Altogether, our findings suggest that the platelet-derived
factor responsible for the inflammasome boosting does not
belong to the classes of nucleic acids, purines, or derivatives
of arachidonic acid.
Therefore, we speculated whether the platelet-derived factor
could be a protein. Ratifying this hypothesis, both heat inactiva-
tion and fixation of platelets (Figure 6E) or platelet supernatants
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(Figure 6F) extinguished their effects on inflammasome activa-
tion in hMDMs. Multiple cytokines were detectable in superna-
tants of resting and activated platelets in our assays (Figure S1A),
including CCL5 (RANTES), CXCL12 (SDF1a), IL-18, and PDGF-
BB. Additional literature reported that platelets are cellular sour-
ces of CD40L, PF4, brain-derived neurotrophic factor (BDNF), P-
selectin, and CXCL7 (Kral et al., 2016; Semple et al., 2011). After
the direct addition of human recombinant proteins to hMDMs
(Figures 6G, S6B, and S6C), inhibitors or blocking antibodies
against platelet-derived cytokines (Figures S6D and S6E), or
co-cultures involving cells from animals deficient for chemokine
receptors (Figure S6F), we excluded a role for CXCL1, CCL5,
CXCL12, CXCL7, PDGF-BB, epidermal growth factor (EGF),
vascular endothelial growth factor (VEGFA), CD40L, PF4,
BDNF, and P-selectin as contributors to the platelet effect.
The failure of the above-mentioned a-granule-derived proteins
to boost IL-1b production in hMDMs suggested that molecules
contained in the dense granules of platelets could mediate the
IL-1b boosting in activated hMDMs. Platelet-dense granules
are rich stores of serotonin (5-HT) and Ca2+. However, we found
that neither the addition of 5-HT (Figure S6G) nor the blockade of
its uptake by hMDMs with fluoxetine (Du et al., 2016; Marcin-
kiewcz et al., 2016) altered IL-1b production by inflammasome-
activated hMDMs (Figure S6H).
We next examined the effect of chelating extracellular or intra-
cellular Ca2+ with 1,2-bis(o-aminophenoxy)ethane-N,N,N0,N0-
tetraacetic acid (BAPTA) and BAPTA-AM, respectively. Notably,
treatment of co-cultures with BAPTA, but not with the
membrane-permeable BAPTA-AM, prevented the platelet
effect without interfering with the basal response of hMDMs
Figure 5. Platelets Enhance NLRP3 and Pro-IL-1 Transcription in Human Macrophages
(A) Caspase-1 activity in cell-free supernatants of NLRP3-overexpressingmousemacrophages ± platelets (50:1 ratio). Cells were left resting (Unstim) or activated
with Nigericin (10 mM, 90 min) without LPS priming.
(B) qPCR analysis of the indicated genes in hMDMs ± platelet supernatants.
(C) Confocal imaging and quantification of ASC specks in LPS-primed and Nigericin-activated hMDMs ± platelets (50:1 ratio). Scale bar, 11 mm.
(D and E) Immunoblotting for IL-1b (D) or caspase-1 (E) in cell-free supernatants, as well as b-actin in cell lysates of resting, LPS-primed hMDMs ± platelets (50:1
ratio), or platelet supernatants. Different donors are indicated.
(F) Caspase-1 activity in cell-free supernatants of hMDMs treated as in (C). Graphs show floating bars (with mean and minimum to maximum values) from pooled
data from three or four independent experiments. Each symbol represents the average of technical triplicates from different donors.
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Figure 6. A Platelet-Derived Ca2+-Dependent Protein Boosts NLRP3 Activity in Human Macrophages
(A) IL-1b released by resting (Unstim), LPS-primed, and Nigericin-activated hMDMs ± aspirin or Zileuton (Zt) pre-treated platelets (50:1 ratio)
(B and C) IL-1b levels released by unstimulated or LPS-primed hMDMs ± platelets. Cells were incubated with Benzonase (B) or Apyrase (C) before LPS priming
and inflammasome activation.
(D) IL-1b levels in co-cultures of platelets and hMDMs added with the indicated concentrations of ADP or equivalent dilutions in water.
(E and F) IL-1b released by hMDMs stimulated as in (A) and co-cultured with heat-inactivated (HI), fixed platelets, or fresch or HI platelet supernatants.
(G) IL-1b released by hMDMs activated as in (A) and added with the indicated recombinant proteins.
(H and I) IL-1b levels in co-cultures of platelets and hMDMs addedwith BAPTA in Ca2+-freemedium (H) or BAPTAAM (I) in normal RPMImedium before activation.
(legend continued on next page)
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(Figures 6H and 6I). However, the addition of calcium chloride
(CaCl2) to inflammasome-activated hMDMs did not evoke addi-
tional IL-1b secretion (Figure S6I), suggesting that Ca2+ is
required but not sufficient for the platelet effect.
Cells sense extracellular Ca2+ primarily through calcium
sensing receptors (CaSR), which are G-protein-coupled recep-
tors (GPCRs). To test the role of CaSR, we pre-treated hMDMs
with the CaSR-selective inhibitor NPS2143. We found that
NPS2143 blocked the platelet effect on hMDMs (Figure 6J). Of
note, recapitulating the platelet effect, allosteric activation of
CaSR with the calcimimetic compound R568 boosted the IL-
1b response of inflammasome-activated hMDMs (Figure 6K).
These findings indicate that a heat-sensitive protein that induces
calcium signaling via CaSR is involved in the platelet-mediated
increase of IL-1b from inflammasome-activated hMDMs.
A Combination of Platelet-Derived Proteins Might Boost
Inflammasome Activation of Macrophages
Next,weassessed theprotein secretomeofplatelets andMKsand
identified additional candidates similarly secreted by these cells
that could mediate the IL-1 boosting effect (Figures 7A, 7B, S7A,
and S7B). Supernatants from quiescent or LPS-treated human
platelets (Figure7A;n=4), aswell as fromMEG-01cells (Figure7B,
n = 3) were evaluated by liquid chromatography-tandem mass
spectrometry (LC-MS). As our findings in Figures 4G and 4H indi-
cated the presenceof a factor ubiquitously present in the superna-
tantsof restingandactivatedplatelets,wedirected further analysis
to proteins that remained unchanged (fold change > 1.5 and <
1.5) following LPS stimulation in both cell types. Among the pro-
teins similarly secreted by platelet and MKs, we identified mem-
bers of the TGF-b and S100 family and thrombospondin-1
(THBS1),whichfiguredas themostabundantprotein inplatelet su-
pernatants (Figures7Aand7B).Notably, TGF-b, S100, andTHBS1
require Ca2+ for their activity (Bertheloot and Latz, 2017; Cailotto
et al., 2011; Misenheimer and Mosher, 1995). Additionally, in line
with our findings that TLR4 signaling is partially involved in the
platelet effect (Figure S1G), THBS1 can activate TLR4 (Li et al.,
2013), can regulate IL-1b in macrophages (Stein et al., 2016),
and is necessary for the full activity of TGF-b (Crawford et al.,
1998). We therefore tested the effect of these proteins on the
(J) IL-1b levels released by inflammasome-activated hMDMs incubated with the indicated concentrations of calcium chloride (CaCl2) in Ca
2+-free medium.
Graphs show floating bars (with mean and minimum to maximum values) from pooled data from two to four independent experiments. Each symbol represents
the average of technical triplicates from different donors.
See also Figure S6.
Figure 7. Platelets Have Broad Effects on Macrophages That May Contribute to Boosting of Inflammasome Activation
(A and B) Proteomics of cell-free supernatants from resting (Unstim) or LPS-treated (A) human platelets (n = 4) or MK (B) (n = 3). Darker points show proteins with
log2 foldR 2 between LPS and Unstim.
(C–G) IL-1b released by resting or inflammasome-activated hMDMs added with (C) rhTGF-b1 or (D) pre-treated with SB-431542, (E) added with rhS100A8/9, (F)
pre-treated with TAK242 (0.5 mg mL1) and an aRAGE mAb (10 mg mL1), or (G) added with rhTHBS1.
(H) IL-1b released by inflammasome-activated BMDMs cultured with WT or Thbs1/ platelet supernatants.
(I) IL-1b and TNF-a levels released by R848-primed and Nigericin-activated hMDMs ± platelets. hMDMs were pre-treated with the CD36 inhibitor SSO. Graphs
show floating bars (with mean and minimum to maximum values) from pooled data from two to four independent experiments
See also Figure S7.
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platelet-mediated boosting of inflammasomes. We tested the
addition of recombinant human TGF-b (rhTGF-b1) to inflamma-
some-activated hMDMs. Consistent with previous reports of an
antagonistic effect of TGF-b on TNF-a signaling (Vaday et al.,
2001; Verrecchia and Mauviel, 2004; Yamane et al., 2003), the
addition of rhTGF-b1 to hMDMs inhibited their production of
TNF-a triggered by LPS (Figure S7C). However, rhTGF-b1 did
not influence the IL-1b response (Figure7C). Likewise, selective in-
hibition of the TGF-b receptor by pre-treating hMDMs with
SB431542 (Matsuyama et al., 2003) did not prevent the platelet
effect (Figure 7D), despite preventing the downregulation of
TNF-a (Figure S7C). These data indicate that TGF-b is likely not
the platelet-derived factor enhancing the NLRP3 activity of
hMDMs, but it might underlie the regulation of TNF-a.
S100 proteins are important regulators of Ca2+ homeostasis,
and platelet-derived S100A8/9 has been shown to induce inflam-
mation (Lood et al., 2016; Wang et al., 2014). S100A8/9 is en-
riched in platelets and binds to membrane receptors such as
TLR4, receptor for advanced glycation endproducts (RAGE),
and CD36 (Bertheloot and Latz, 2017). TLR4 and CD36 are
also known receptors for THBS1 (Li et al., 2013; Stein et al.,
2016). However, we found that addition of neither rhTHBS1 (Fig-
ures 7G and S7E) nor rhS100A8/9 (Figure 7E) to hMDMs influ-
enced their basal response to LPS + Nigericin. Of note,
rhS100A8/9 induced TNF-a secretion from hMDMs (Figure S7D).
Furthermore, supernatants from Thbs1/ platelets were as effi-
cient as WT platelets in boosting IL-1b release and caspase-1
activity from inflammasome-activated BMDMs (Figure 7H), and
RAGE inhibition antibodies had no effect on the platelet boosting
of IL-1b (Figures 7F and S7G). These findings led us to conclude
that platelet-derived THBS1 and S100A8/A9 are not, individually,
responsible for the platelet effect on macrophages.
As THBS1 and S100 proteins bind to CD36, we tested the ef-
fect of CD36 inhibition with Sulfosuccinimidyl oleate (SSO) (Kuda
et al., 2013). SSO interfered with IL-1b and TNF-a release (Fig-
ure 7I) and caspase-1 activity (Figure S7F) in both the presence
and absence of platelets. Nevertheless, even in the presence of
SSO, platelets increased both the release of IL-1b and the activ-
ity of caspase-1 from macrophages compared to SSO-pre-
treated macrophages in monoculture.
As single inhibition of TLR4, RAGE, and CD36 did not
completely abrogate the platelet effect, we speculated that a
combined activity of platelet-derived S100 and THBS1 could
mediate the boosting of IL-1b on hMDMs. An experimental strat-
egy to block TLR4/RAGE and CD36 resulted in complete inhibi-
tion of IL-1b, TNF-a, and caspase-1 activity of hMDMs (Fig-
ure S7G), thus precluding us to conclude whether these
proteins are synergistically involved in the platelet-mediated
enhancement of IL-1b response of hMDMs. Hence, additional
work is required to delineate the mechanisms by which platelets
affect the inflammasome activation of hMDMs.
DISCUSSION
Here, we report that the interaction with platelets licenses
NLRP3, potentiates inflammasome activation and production
of IL-1 cytokines by innate immune cells, and is critical for
NLRP3-activation in human monocytes. The platelet effect is
mediated by a yet unidentified soluble factor (or factors), which
enhances NLRP3 transcription and boosts inflammasome acti-
vation. Hence, our work identifies platelets as additional players
in governing the production of IL-1 cytokines and emphasizes
that full inflammasome activity in vivo is too complex to be
modeled by in vitro monocultures of single-cell populations.
Platelets are key players in inflammation (Carestia et al., 2019;
Dann et al., 2018; Kral et al., 2016; Passacquale et al., 2011) and
express TLRs that sense infection and initiate inflammatory re-
sponses (Andonegui et al., 2005). While platelets are known to
react to LPS (Cognasse et al., 2008; Andonegui et al., 2005),
they do not constitutively express membrane CD14 (Damien
et al., 2015) and require soluble CD14 from plasma for TLR4
signaling (Brown and McIntyre, 2011; Damien et al., 2015).
Our work adds to a growing bulk of evidence that platelet pa-
rameters, such as their blood counts, can be additional causes of
variation in the concentrations of circulating cytokines (Hu et al.,
2018; Schirmer et al., 2018; Tunjungputri et al., 2018). Platelets
secrete a large array of proteins (Coppinger et al., 2004;Maynard
et al., 2007), which affect leukocytes in different ways (Kral et al.,
2016; Sreeramkumar et al., 2014). They have also been pro-
posed as sources of IL-1 cytokines and, more recently, to
assemble inflammasomes (Cornelius et al., 2019; Hottz et al.,
2013; Vogel et al., 2018).
Our work challenges these findings with a series of comple-
mentary techniques that demonstrate that platelets lack expres-
sion of NLRP3, ASC, and caspase-1 and are therefore incapable
of assembling inflammasomes. Those included experiments us-
ing platelets and BMDMs frommice lacking IL-1 proteins or their
receptors (Figures 4A–4C); mice lacking inflammasome mole-
cules (Figure S2D), megakaryocytes, and platelets from humans
(Figures S3F, S3G, and S4); and transgenic or knockin inflamma-
some reporter mice (Figures S3C–S3E), as well as a MS-based
proteomics analysis of supernatants from human platelets and
MKcell line (Figures 7 andS7). Our conclusionswere further sup-
ported by a meta-analysis of transcriptomics from five indepen-
dent studies with human platelets (Figure S5). We believe that
the discrepancies are likely because the studies reporting in-
flammasomes on platelets relied on fluorescence assessment
of inflammasome components, using antibodies of weak speci-
ficity (Beilharz et al., 2016), and without quantitative measure-
ment of proteins in platelet lysates by immunoblotting. Likewise,
IL-1 expression on platelets is reported with conflicting results in
literature. Some studies describe expression of IL-1 in activated
platelets (Denis et al., 2005; Lindemann et al., 2001; Thornton
et al., 2010), while others find IL-1 activity in bioassays (Hawrylo-
wicz et al., 1989; Kaplanski et al., 1993), with no evidence of the
cytokine itself. Notably, throughout all our experiments, we as-
sessed the purity (leukocyte contamination CD14 and/or CD45;
Figures S3C–S3E, S4D, and S4F) as well as activation capacity
(ability to upregulate CD62p upon thrombin stimulation; Figures
S3F and S4E) of our platelet preparations. These important con-
trols were not performed in the aforementioned studies. Hence,
it cannot be ruled out that their platelet preparations are free of
contaminating leukocytes (Pillitteri et al., 2007). For example, a
preparation of 5 3 108 platelets, commonly used in previous
studies for RNA isolation, with a 98% purity (assessed by
FACS) could easily contain 2 3 106 contaminating leukocytes,
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which could account for a significant portion of RNA within a
sample. Supporting this, IL-1b expression on platelet prepara-
tion is closely correlated to the presence of contaminating leuko-
cytes (Pillitteri et al., 2007).
In line with our findings, platelets have been reported to
amplify IL-1b-mediated inflammation in RA (Boilard et al.,
2010), an IL-1-driven disease (Dinarello, 2011), and a recent
study demonstrated pro-atherogenic effects of platelets by
and skewing monocytes into a pro-inflammatory macrophage
phenotype (Barrett et al., 2019). Platelet depletion in mice with
RA (Boilard et al., 2010) or in Ldlr–/– mice fed a western diet (Bar-
rett et al., 2019) attenuated inflammation and improved clinical
outcomes. However, it was not possible in these studies to
distinguish whether these effects were caused by decreased
platelet-derived cytokines or by the influence of platelets on
other immune cells, as we report here.
Our data confirm their relevance to human physiology and
disease, as high blood platelet counts are found in patients (Cic-
carelli et al., 2014) andmousemodels of IL-1-driven auto-inflam-
matory disorders (Bonar et al., 2012). In Kawasaki disease (KD),
an acute systemic vasculitis in children for which thrombocytosis
is a common feature, human and experimental mouse models
have determined a critical role of IL-1b in the cardiovascular
pathogenesis. Furthermore, thrombocytosis and platelet activa-
tion are predictive of the development of coronary aneurysm in
KD (Burns et al., 2017; Lee et al., 2012b).
As both IL-1a and IL-1b induce thrombocytosis in mice (Ki-
mura et al., 1990; Nishimura et al., 2015; Trinh et al., 2015), plate-
lets could help feed an inflammatory loop by potentiating IL-1
signaling, which in turn triggers platelet biogenesis. However,
whether thrombocytosis is a marker of disease or a contributor
to pathogenesis remains to be investigated. Platelet counts
have been correlated with the concentrations of other cytokines
that affect platelet production in immune thrombocytopenia (ITP)
and other diseases. Those include CD40L, CXCL5, CCL5, EGF,
VEGF, granulocyte-macrophage colony-stimulating factor (GM-
CSF), interferon (IFN)g, monocyte chemoattractant protein 1
(MCP-1), IL-8, and PDGF-BB (Feng et al., 2012; Pourcelot
et al., 2014). Thus, the contribution of platelets to cytokine pro-
duction in human biology warrants further investigation.
Notably, co-culture with platelets impaired the LPS-induced
TNF-a production in several immune cells. This observation is
in line with previous studies (Aslam et al., 2006; Gudbrandsdottir
et al., 2013; Xiang et al., 2013) and may be explained by the re-
ported ability of platelets to sequester TNF-a and IL-6 released
from LPS-stimulated monocytes (Carestia et al., 2019). Platelets
have a protective role in sepsis through the regulation of TNF-a
and IL-6 via the secretion of a COX1/PGE2/EP4-dependent lipid
mediator (Xiang et al., 2013). In line with these findings, we
observed that TNF-a is regulated via a platelet-derived COX1-
dependent lipid mediator and is related to TGFb signaling.
Despite our efforts, wewere unable to identify a unique platelet
factor that boosts the inflammasome activation of innate im-
mune cells. However, we show that the regulation of IL-1b pro-
duction is likely mediated through a constitutively expressed
protein factor that engages a CaSR on primary human macro-
phages. This is consistent with previous reports of roles for
CaSR on inflammasome activation (Lee et al., 2012a; Rossol
et al., 2012). These findings will need further validation using ge-
netic deletion of these receptors. It is possible that a combination
of factors acting in synergy and affecting different pathways un-
derlie the platelet effect.
Our findings also strengthen recent discoveries of a direct link
between themammalian immune and coagulation systems (Bur-
zynski et al., 2019; Wu et al., 2019; Yang et al., 2019) by showing
a direct participation of platelets in the inflammasome output of
innate immune cells.
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Antibodies
Anti-human Caspase-1 (p20), mAb (Bally-1) Adipogen International AG-20B-0048-C100; RRID:AB_2490257
Anti-human CD14-APC (61D3) Thermo Fisher Scientific 17-0149-42; RRID:AB_10669167
Anti-human CD41 FITC (HIP8) Thermo Fisher Scientific 11-0419-42; RRID:AB_10718234
Anti-human CD45 PE (2D1) Thermo Fisher Scientific 12-9459-42; RRID:AB_10718238
Anti-human CD66b Thermo Fisher Scientific 11-0666-42; RRID:AB_2572461
Anti-human NAP2 (CXCL7) PeproTech 300-14-10; RRID:AB_147531
Anti-human RAGE R&D Systems MAB11451; RRID:AB_2224344
Anti-mouse CD41 eFluor450 (eBioMWReg30) Thermo Fisher Scientific 48-0411-82; RRID:AB_1582238
Anti-mouse CD45 PE (30-F11) Thermo Fisher Scientific 12-0451-83; RRID:AB_465669
Anti-human CXCL12 / SDF-1a R&D Systems AF-310-SP; RRID:AB_354461
Anti-human IL-1 beta / IL-1F2 Antibody, goat R&D Systems AF-201-NA; RRID:AB_354387
Anti-mouse IRDye 680 Li-Cor Biosciences 925-68080; RRID:AB_2814917
Anti-mouse Ly6G-AF488 (RB6-8C5) Thermo Fisher Scientific 53-5931-82; RRID:AB_469918
Anti-mouse Ly6G-APC (1A8-ly6g) Thermo Fisher Scientific 17-9668-82; RRID:AB_2573307
Anti-mouse NLRP3/NALP3, mAb (Cryo-2) Adipogen International AG-20B-0014; RRID:AB_2490202
Anti-human/mouse CD62p (P-selectin) APC (Psel.KO.2.3) Thermo Fisher Scientific 12-0628-42; RRID:AB_10804401
Anti-human/mouse Beta-Actin (Host: mouse) Li-Cor Biosciences 926-42212; RRID:AB_2756372
Anti-human/mouse Beta-Actin (Host: rabbit) Li-Cor Biosciences 926-42210; RRID:AB_1850027
Anti-human/mouse Beta-Tubulin (Host: rabbit) Li-Cor Biosciences 926-42211; RRID:AB_1850029
Anti-rabbit IRDye 800 Li-Cor Biosciences 926-32213; RRID:AB_621848
FcR Blocking Reagent, human Miltenyi Biotech 130-059-901
FcR Blocking Reagent, mouse Miltenyi Biotech 130-092-575
Mouse IgG1 K Iso Control APC (P3.6.2.8.1) Thermo Fisher Scientific 17-4714-42; RRID:AB_1603315
Mouse IgG1 K Iso Control FITC (P3.6.2.8.1) Thermo Fisher Scientific 11-4714-42; RRID:AB_10596964
Mouse IgG1 K Iso Control PE (P3.6.2.8.1) Thermo Fisher Scientific 12-4714-42 RRID:AB_1944423
Normal Goat IgG control R&D systems AB-108-c; RRID:AB_354267
OneComp eBeads Thermo Fisher Scientific 01-1111-42
Polyclonal anti-GPIb alpha Emfret Analytics R300; RRID:AB_2721041
Polyclonal non-immune rat immunoglobulins Emfret Analytics C301; RRID:AB_2734715
Purified anti-ASC (TMS-1) Antibody BioLegend 653902; RRID:AB_2561778
Purified anti-human CD42b Antibody (HIP1) BioLegend 303902; RRID:AB_314382
Purified Mouse IgG, k Isotype BioLegend 401402; RRID:AB_2801451
Rat Anti-mouse CD14-FITC (Sa14-2) BioLegend 123308; RRID:AB_940580
Rat IgG1 K Iso Control eFluor450 (eBRG1) Thermo Fisher Scientific 48-4301-82; RRID:AB_1271984
Rat IgG2a K Iso Control APC (eBR2a) Thermo Fisher Scientific 17-4321-81; RRID:AB_470181
Rat IgG2b, K Iso Control PE (eB149/10H5) Thermo Fisher Scientific 12-4031-82; RRID:AB_470042
Chemicals, Peptides, and Recombinant Proteins
2-mercaptoethanol Sigma-Aldrich M6250-250ML
Acetylsalicylic acid (Aspirin) Sigma-Aldrich A5376-100G
Acid-Citrate-dextrose solution (ACD) Sigma-Aldrich C3821-50ML
Adenosine 5-diphosphate sodium salt (ADP) Sigma-Aldrich A2754-500MG
Adenosine triphosphate (ATP) Sigma-Aldrich A2382
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Apyrase from potatoes, High Activity, ATPase >
600 units/mg protein
Sigma-Aldrich A2230-100UN
BAPTA AM Enzo Life Sciences Inc BML-CA411-0025
BAPTA, Tetrasodium salt Santa Cruz Biotechnology sc-278716
Benzonase Nuclease Sigma-Aldrich E1014-5KU
Bovine Serum Albumin (BSA) Sigma-Aldrich A9647
Calcium chloride Sigma-Aldrich 21115-100ML
Chloroform Merck 1.02445.1000
cOmplete EDTA-free protease inhibitor Cocktail Tablets Sigma-Aldrich 4693132001
CRID3 (CP-456773-02, MCCP90) Sigma-Aldrich PZ0280
Cutasept F Haut-Desinfiziens Hartmann 9803640
Cytochalasin D Sigma-Aldrich C8273-1MG
D-(+)-Glucose solution Sigma-Aldrich G7021-100 g
Di-Sodium hydrogen phosphate (Na2HPO4) Sigma-Aldrich 255793
Dimethyl sulfoxide (DMSO), cell culture grade PAN-Biotech P60-36720100
Dithiothreitol (DTT) Thermo Fisher Scientific Y00147
dNTP Mix (10 nM each) Thermo Fisher Scientific R0192
DRAQ5 Thermo Fisher Scientific 65-0880-96
Ethanol (EtOH) absolute AppliChem 147194.1214
Fetal Bovine Serum (FBS) Thermo Fisher Scientific 26140079
Ficoll-Paque PLUS GE Healthcare 17-1440-03
GIBCO Dulbecco’s Dulbecco’s Modified Eagle
Medium (DMEM)
Thermo Fisher Scientific 41965039
GIBCO Dulbecco’s Phosphate Buffered Saline (PBS) Thermo Fisher Scientific 14190144
GIBCO GlutaMAX 100X Thermo Fisher Scientific 35050061
GIBCO Penicillin-Streptomycin (10,000 U/mL) Thermo Fisher Scientific 15140122
GIBCO RPMI 1640 Medium Thermo Fisher Scientific 21875091
GIBCO Sodium Pyruvate 100mM Thermo Fisher Scientific 11360070
GIBCO UltraPure 0.5M EDTA, pH 8.0 Thermo Fisher Scientific 15575020
Hoechst 34580 Thermo Fisher Scientific H21486
L929 cell line supernatant Gift from Prof. Latz and
Ms. Engels (University of Bonn)
N/A
Lipopolysaccharide (LPS), ultrapure, E. coli 0111:B4 Invivogen tlrl-3pelps
Magnesium chloride (MgCl2) solution Sigma- Aldrich M1028-100ML
Methanol Merck 1.06007.2500
Met-RANTES trifluoroacetate salt, human Bachem H-6544.0050
Nigericin, free acid Invitrogen N1495
Oligo(dT)18 primer Thermo Fisher Scientific SO132
PageRulerTM Plus Prestained Protein Ladder,
10 to 250kDa
Thermo Fisher Scientific 26619
Pam3Cysk4 InvivoGen P2200.0005
PhosSTOP Easypack Phasphatase Inhibitor
Cocktail Tablets
Sigma-Aldrich 04906837001
Piperazine-1,4-bis(2ethanesulfonic acid) (PIPES) Sigma-Aldrich P6757-25G
Poly-L-Lysine solution Sigma-Aldrich P4707
Potassium chloride (KCl) Sigma-Aldrich P9327-100ML
(LFn-)PrgI fusion protein Gift from Prof. Geyer and
Dr. Fußho¨ller (University of Bonn)
N/A
Prostaglandin E1 (PGE-1) Sigma-Aldrich P5515-1MG
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Protective antigen (PA), recombinant from
Bacillus anthracis
List Biological Laboratories 171C
R848 Invivogen tlrl-r848-5
Recombinant human BDNF Tocris Bioscience 2837
Recombinant human CD40L / CD154, soluble Enzo Life Sciences ALX-522-015-C010
Recombinant human EGF Sigma-Aldrich E9644
Recombinant human GM-CSF Immunotools 11343125
Recombinant human GRO-alpha / MGSA (CXCL1) PeproTech 300-11-5UG
Recombinant human NAP-1 (CXCL7) PeproTech 300-14-10
Recombinant human P-selectin R&D systems ADP3
Recombinant human PF4 (CXCL4) PeproTech 300-16-5UG
Recombinant human PGDF-BB BioLegend 577304
Recombinant human PLGF-1 (PIGF-1) Thermo Fisher Scientific PHG0296
Recombinant human RANTES (CCL5) Thermo Fisher Scientific PHC1054
Recombinant human S100A8/S100A9 heterodimer R&D Systems 8226-S8-050
Recombinant human SDF-alpha (CXCL12) PeproTech 300-28a-10UG
Recombinant human TGF-b1 PeproTech 100-21C-2UG
Recombinant human THBS-1 Sigma-Aldrich ECM002-50UG
Recombinant human VEGF Thermo Fisher Scientific PHC9394
SB431542 Invivogen inh-sb43
Sodium chloride (NaCl) Sigma- Aldrich S5150-1L
Sodium deoxycholate Sigma- Aldrich D-6750-10G
Sodium dodecyl sulfate (SDS) Sigma- Aldrich 75746-1KG
Sodium hydroxide (NaOH) Sigma- Aldrich S2770-100ML
Sulfo-N-succinimidyl Oleate sodium (SSO) BioMol Cay11211-5
TAK242 (Resatorvid) Invivogen tlrl-cli95
Thrombin from human plasma Sigma-Aldrich T6884-100UN
Triton X-100 Carl Roth 3051.3
Tween 20 Sigma- Aldrich P2287
UK5099 BioMol Cay16980-5
Wheat Germ Agglutinin (WGA) Alexa Fluor 555 Thermo Fisher Scientific W32464
Zileuton Tocris 3308
GIBCO Opti-MEM Thermo Fisher Scientific 31985070
Lipofectamine 2000 Transfection Reagent Thermo Fisher Scientific 11668019
Poly [dA:dT] Sigma P0883
Critical Commercial Assays
Alexa Fluor 647 Antibody labeling kit Thermo Fisher Scientific A20186
Caspase-Glo 1 Inflammsome Assay Promega G9952
CD14 MicroBeads, human Miltenyi Biotech 130-050-201
EasySep Direct Human Neutrophil Isolation Kit STEMCELL Technologies 19666
EasySep Human Monocyte Isolation Kit Stemcell 19359
Human IL1 beta HTRF kit Cisbio 62IL1PEB
Human TNF alpha HTRF kit Cisbio 62TNFPEB
Maxima SYBR Green/ROX qPCR Master Mix Thermo Fisher Scientific K0221
Mouse IL1 beta HTRF kit Cisbio 63ADK010PEB
Mouse IL6 HTRF kit Cisbio 63ADK043PEB
Mouse TNF alpha HTRF kit Cisbio 6FMTNPEB
Pierce BCA Protein Assay Kit Thermo Fisher Scientific 23225
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Pierce LDH Cytotoxicity Assay Kit Thermo Fisher Scientific B3026-88954
ProcartaPlex Human Cytokine/Chemokine/
Growth Factor Panel 1 45plex
Thermo Fisher Scientific EPX450-12171-901
RNase-Free DNase Set QIAGEN 79254
RNeasy Mini Kit QIAGEN 74106
S-Monovette 9NC tubes Sarstedt 01.1606.001
S-Monovette K3EDTA tubes Sarstedt 02.1066.001
SuperScript III First-Strand Synthesis SuperMix Thermo Fisher Scientific 18080-400
Deposited Data
Transcription profiling of whole blood from pediatric
patients Muckle-Wells disease and healthy childreen
Balow et al., 2013 Accession Nr.: GSE43553
Transcription profiling of human platelets from patients
with essential thrombocythemia
Gnatenko et al., 2005 Accession Nr.: E-GEOD-2006
Transcription profiling of human platelets from patients
with dengue shock syndrome
Devignot et al., 2010 Accession Nr.: GEOD17924
Transcription profiling of human platelets from patients
with sickle cell disease
Raghavachari et al., 2007 Accession Nr.: E-GEOD-11524
Transcription profiling of human platelets from patients
with sepsis-induced acute lung injury (ALI)
Freishtat et al., 2009 Accession Nr.: E-GEOD-10361
Transcription profiling of human platelets from patients
with Polycythemia Vera (PV)
Spivak et al., 2014 Accession Nr.: E-GEOD-47018
Raw Mass Spectrometry Data Files This paper Data are available via ProteomeXchange:
PXD017976
Experimental Models: Cell Lines
NLRP3-FLAG overexpressing immortalized NLRP3 KO (Franklin et al., 2014; Stutz et al., 2013)
THP-1 ATCC ATCC TIB-202
MEG01 ATCC CRL2021
Experimental Models: Organisms/Strains
Mus musculus, wild-type (C57BL/6j) The Jackson Laboratory Stock 000664
Mus musculus, ASC-mCitrine Tg (B6.Cg-Gt(ROSA)
26Sortm1.1(CAG-Pycard/mCitrine*,-CD2*)Dtg/J)
The Jackson Laboratory Stock 030744
Mus musculus, Nlrp3–/– mice (B6.B6N-Nlrp3tm1Vmd) Mariathasan et al., 2006 N/A
Mus musculus, Asc–/– mice (B6.129-Pycardtm1Vmd) Mariathasan et al., 2004 N/A
Mus musculus, Il1b–/– mice (B6.129S2-Il1btm1Dch) Shornick et al., 1996 N/A
Mus musculus, Il1r–/– mice (B6.129S7-Il1r1tm1Imx/J) The Jackson Laboratory Stock 003245
Mus musculus, Il18r–/– mice (B6.129P2-Il18r1tm1Aki/J) The Jackson Laboratory Stock 004131
Mus musculus, Cd36–/– mice (B6.129S1-Cd36tm1Mfe/J) The Jackson Laboratory Stock 019006
Mus musculus, Tsp1–/– mice (B6.129S2-Thbs1
(tm1Hyn)/J)
The Jackson Laboratory Stock 006141
Mus musculus, Cxcr3–/– mice (B6.129P2-
Cxcr3tm1Dgen/J)
The Jackson Laboratory Stock: 005796
Mus musculus, Ccr5–/– mice (B6.129P2-Ccr5tm1Kuz/J) The Jackson Laboratory Stock: 005427
The knock in ASC-mCherry reporter mouse is available
upon request
Eicke Latz, Institute of Innate
Immunity
N/A
Oligonucleotides
hACTB-Fwd: 50-ccaccatgtaccctggcatt-30 Metabion N/A
hACTB-Rev: 50-cggagtacttgcgctcagga-30 Metabion N/A
hNLRP3-Fwd: 50-tcggagacaaggggatcaaa-30 Metabion N/A
hNLRP3-Rev: 50-agcagcagtgtgacgtgagg-30 Metabion N/A
hCD14-Fwd: 50-gagctcagaggttcggaaga-30 Metabion N/A
(Continued on next page)
Cell Reports 31, 107615, May 12, 2020 e4
Article
ll
OPEN ACCESS
RESOURCES AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Bernardo
S Franklin (franklin@uni-bonn.de).
Materials Availability
This study did not generate new unique reagents. The knockin ASC-mCherry reporter mouse is available upon request.
Data and Code Availability
The mass spectrometry proteomics data are available via ProteomeXchange: PXD017976.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Study Subjects
Peripheral blood was obtained by venipuncture of healthy volunteers after signature of informed consent, and approval of the study
by the Ethics Committee of the University of Bonn (Protocol #282/17), and in accordance with the Declaration of Helsinki.
Malaria patients naturally infectedwithPlasmodium vivax in the Amazon area of Cuiaba (Mato Grosso, Brazil) were invited to partic-
ipate in the study. Seventy-eight individuals (aged 18 - 78 years old) who sought care at the Julio Muller Hospital, whose thick blood
smear was positive for P. vivax were included. Another 9 healthy volunteers from the same endemic area who tested negative for
Plasmodium infection were recruited and served as healthy donor controls. Exclusion criteria included: (i) refuse or inability to
sign the informed consent; (ii) age < 18 years; (ii) pregnant women; (ii) mixed infection with P. falciparum or P. malariae, tested by
both microscopic examination and a nested-PCR; (iv) any other comorbiditythat could be traced. Clinical and demographical
data were acquired through a standardized questionnaire, and the hematological profiles were assessed by automated complete
blood count carried out at the site hematology facility. Plasma samples were isolated immediately after blood sampling and stored
at 80C until use. The study was approved by the Ethical Review Board of the Rene´ Rachou Research Center, FIOCRUZ, Brazilian
Ministry of Health (Reporter CEPSH/CPqRR N. 05/2008 and N. 01/2018).
All participants were instructed about the objectives of the study and signed an informed consent in accordance with guidelines for
human research, as specified by the Brazilian National Council of Health (Resolution 196/96). Patients diagnosedwithP. vivaxmalaria
were treated according to the standard protocols recommended by the National Malaria Control Program (chloroquine +
primaquine).
Mice
Mice were housed under standard conditions at 22C and a 12 h light-dark cycle with free access to food and water. Animal care,
handling and experimentation was approved by the ethical committee in Bonn: LANUV-NRW #84-02.04.2016.A487), and in Ribeir~ao
Preto, S~ao Paulo (149/2019). Male 8 – 12 week old C57BL/6j mice were used for experimentation. Male and female 8 week old
C57BL/6j, Nlrp3–/–, Asc–/–, Casp-1–/–, Il1b–/–, IL1r–/–, IL18r–/–, Tsp1–/–, Cd36–/–, Cxcr3–/–, Ccr5–/–, and ASC-mCitrine Tg mice were
used as source of primary cells.
Continued
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hCD14-Rev: 50-cttcatcgtccagctcacaa-30 Metabion N/A
hPYCARD-Fwd: 50-gagctcaccgctaacgtgct-30 Metabion N/A
hPYCARD-Rev: 50-actgaggaggggcctggat-30 Metabion N/A
hPF4- Fwd: 50-ctgaagaagatggggacctg-30 Metabion N/A
hPF4- Rev: 50-gtggctatcagttgggcagt-30 Metabion N/A
hCASP1-Fwd: 50-acaacccagctatgcccaca-30 Metabion N/A
hCASP1-Rev: 50-gtgcggcttgacttgtccat-30 Metabion N/A
hBP1BA-Fwd: 50-ctgctctttgcctctgtggt-30 Metabion N/A
hBP1BA-Rev: 50-ctccaggtgtgtggtttgtg-30 Metabion N/A
hIL1B-Fwd: 50-tgggcagactcaaattccagct-30 Metabion N/A
Software and Algorithms
GraphPad Prism 8.1.2 (227) https://www.graphpad.com RRID:SCR_002798
FlowJo 10.4 https://www.flowjo.com RRID:SCR_008520
Volocity 3D Image Analysis Software v6.0.1 https://www.perkinelmer.com RRID:SCR_002668
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Cell lines
The monocytic cell line THP-1 (ATCC TIB-202), and the megakaryocytic cell line MEG-01 (ATCC CRL-2021) were cultured in RPMI-
1640 medium supplemented with 10% FBS, 1% Penicillin/Streptomycin and GlutaMAX (1x) at 37C with 5% CO2.
METHODS DETAILS
Data Presentation
Unless indicated otherwise (in Figure legends), all graphs are represented as Floating Bars (with mean, and minimum to maximum
values) and are built from pooled data from a minimum of two independent experiments (biological replicates), performed in tripli-
cates (technical replicates) with immune cells or platelets from different donors. For experiments performed less than 3 times, bar
graphs with mean and standard deviation (SD) are shown. Each symbol represents the average from 3 technical replicates per
each donor, experiment, or mouse. Symbols are coded (C,,,:,;, etc.) to indicate donors so readers can track the internal vari-
ability between different donors, mice, or experiments. Dots are semi-transparent, with darker symbols indicating overlapping points.
Generation of human primary macrophages
Buffy coats from healthy donors were obtained according to protocols accepted by the institutional review board at the University of
Bonn (local ethics votes Lfd. Nr. 075/14). Primary humanmacrophages were obtained through differentiation of CD14+monocytes in
a medium complemented with 500 U ml-1 rhGM-CSF (Immunotools) for 3 days. In brief, human peripheral blood mononuclear cells
(PBMCs) were obtained from buffy coats of healthy donors by density gradient centrifugation in Ficoll-Paque PLUS (Healthcare).
PBMCs were incubated at 4C with magnetic microbeads conjugated to monoclonal anti-human CD14 antibodies according to
the manufacturer’s instructions (Miltenyi Biotech). CD14+ monocytes were thereby magnetically labeled and isolated using a
MACS column placed in a magnetic field. CD14+monocytes were cultivated in complete medium (RPMI1640 medium with 10%
FBS, 1% Penicillin-Streptomycin, 1% GlutaMAX and 1% Sodium Pyruvate) complemented with 500 U ml-1 rhGM-CSF at a concen-
tration of 2x106 ml-1 in 6-well plates to generate monocyte-derived macrophages. Cells were harvested at day 3, counted using a
hemocytometer and seeded at a concentration of 1x105/well in complete medium complemented with 125 U ml-1 rhGM-CSF in
96-well flat-bottom plates and incubated overnight for experiments on the next day.
Generation of mouse bone marrow macrophages
Mice were anaesthetized and sacrificed by cervical dislocation. Femur and tibia from hind limbs were removed and the bones were
briefly disinfected with 70% ethanol. The bone marrow cavity was flushed with PBS and the cell suspension was filtered through a
70 mm cell strainer before centrifugation at 400 x g for 5 minutes. Cells were resuspended in DMEM supplemented with 20% L929
supernatant and cultured for 6 days to differentiate into macrophages (BMDMs). On day six, cells were harvested using cold PBS
containing 5 mM EDTA and 2% FBS and scraping. After centrifugation at 350 x g for 5 minutes, the BMDM were seeded at
1x105/well in DMEM with 20% L929 supernatants in flat-bottom 96-well plates and incubated overnight for experiments on the
next day.
Isolation of CD14+ human Monocytes
Venous blood was collected in S-Monovette K3EDTA tubes and PBMCs were obtained by density gradient centrifugation in Ficoll-
Paque PLUS. Monocytes were isolated from PBMCs using the EasySepTM Human Monocyte Isolation Kit according to the manu-
facturer instructions (STEMCELL TechnologiesTM). PBMCs were washed twice with PBS complemented with 2% FBS and 1mM
EDTA before incubated with the suppliedmonocyte isolation cocktail and the platelet removal cocktail for 5minutes. Magnetic beads
were added to this suspension for another 5 minutes before magnetic separation in an EasySepTM Magnet. After 2.5 minutes of in-
cubation, the enriched suspension was poured into a new tube. The isolated monocytes were counted using a hemocytometer and
resuspended in RPMImedium at a concentration of 1x106ml-1 . The purity of the purifiedmonocytes was assessed by flow cytometry
using CD14 (monocyte) and CD41 (platelet) markers.
Isolation of Human Neutrophils
Venous blood was collected in S-Monovette K3EDTA tubes and neutrophils were isolated using the EasySepTM Direct Human
Neutrophil Isolation Kit according to the manufacturer instructions (STEMCELL TechnologiesTM). Whole blood was incubated with
the Neutrophil Isolation Cocktail and RapidSpheresTM for 5 minutes and diluted with neutrophil isolation buffer (1mM EDTA in
PBS). After 5 minutes of incubation in the EasySepTM Magnet, the enriched cell suspension was poured into a new tube and incu-
bated again with RapidSpheresTM for another 5 minutes, followed by a second, and third round of magnetic separation. The
obtained neutrophils were counted using a hemocytometer and pelleted by centrifugation at 350 x g for 5 minutes. Cells were resus-
pended in RPMI-1640medium supplemented with 10% FBS, 1%GlutaMAX and 1%Penicillin-Streptomycin. Neutrophil suspension
was adjusted to 1x106 ml-1 and 100 mL (1x105cells/well) were seeded in a 96-well round-bottom plate. The purity of the purified neu-
trophils was assessed by flow cytometry using CD66b (neutrophil marker) and CD41 (platelet marker).
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Isolation of Human Platelets
Human platelets were isolated as previously described (Alard et al., 2015) with slight modifications. In brief, venous blood was drawn
into S-Monovette 9NC collection tubes. The blood was centrifuged for 5 minutes at 330 x g without brake to obtain platelet-rich
plasma (PRP). All following centrifugation steps were performed without brake and in the presence of 200 nM PGE1 to inhibit platelet
activation. PRP was transferred to a new tube and diluted 1:1 with phosphate-buffered saline (PBS) to reduce leukocyte contamina-
tion and centrifuged for 10 minutes at 240 x g. Platelets were pelleted by centrifugation at 430 x g for 15 minutes and washed once
with PBS. Total platelets were counted using a hemocytometer and resuspended in RPMI medium to a concentration of 1x108 ml-1
unless otherwise indicated. The purity of the purified platelets was assessed by flow cytometry using CD45 (leukocyte) and CD41
(platelet) markers.
Isolation of Mouse Platelets
Blood was drawn by puncturing the vena facialis of anaesthetized mice. Blood from mice of the same genotype were pooled in a
sterile 5 mL polystyrene tube containing one-sixth blood volume of pre-warmed citrate-dextrose solution (ACD). PRP was prepared
by centrifugation at 330 x g for 5 minutes without break. All following centrifugation steps were performed without brake. PRP was
transferred to a new tube and diluted in twice as much volume of PIPES/saline/glucose (PSG) buffer with the final concentration of
1.5 mM PGE1. The suspension was centrifuged at 240 x g for 10 minutes to reduce leukocyte and erythrocyte contamination. The
supernatant was transferred into a tube with PGE1 in a final concentration of 0.7 mM in PSG buffer. The platelets were pelleted by
centrifugation at 1000 x g for 5 min, washed with 1.5 mM PGE1 in PSG buffer. The washed platelets were resuspended in DMEM,
counted in a hemocytometer, and the platelet suspension was adjusted to 5x106 ml-1 unless otherwise indicated. Purity and viability
of the prepared platelets were assessed by flow cytometry.
Purity Assessment of Cells Populations
Samples of isolated neutrophils and platelets were analyzed for purity, platelet pre-activation and platelet viability after each exper-
iment. Isolated murine and human platelets were activated with 0.5 or 1 U ml-1 thrombin respectively for 30 min. Cells were blocked
with 1:10 mouse or human Fc blocking reagent for 10 minutes at room temperature (RT). The samples were stained with fluoro-
chrome-conjugated monoclonal anti-mouse or anti-human Ig antibodies against CD41/CD41, CD62p, CD14, CD45 or CD66b as
indicated for 30 minutes in the dark. Cells were washed and resuspended in flow cytometry buffer (1% FBS in PBS) for analysis.
Compensation beads (OneComp Beads) and isotype controls were prepared in the same way. Flow cytometry was performed
with a Macs Quant Analyzer10 (Miltenyi Biotech) and analyzed using the Flowtop software (Tree Star). The applied gating strategy
was based on doublet discrimination and isotype-matched control antibodies.
Platelet depletion and LPS + R848 model
Platelet depletion was performed in male, 6-10 week-old C57BL/6j mice by intravenous injection of an anti-CD42b (GPIb-alpha)
monoclonal antibody or its isotype IgG control (Emfret Analytics, 2 mg/g animal, 100 mL). 6 hours after injection, a drop of blood
was taken from the tail vein to confirm the efficiency of platelet depletion by flow cytometry. Next, the animals were intraperitoneally
injected with 200 mg of R848 (Resiquimod, Invivogen) or a combination of 200 mg of R848 and 200 mg of LPS (E.coli O111:B4, Inviv-
ogen) in equal volumes (100 mL) as described (Kanneganti et al., 2006). The collection of samples was conducted 6 hours after the
inflammatory stimuli. Blood was centrifuged for 10 minutes at 5000 rpm, 4C for collection of serum. Peritoneal lavage was centri-
fuged for 5 minutes at 500 g, 4C and the cells from the peritoneal lavage were fixed and stained for phenotyping. Blood and cell-free
peritoneal exudate were used for the cytokine evaluation (R&D Systems).
Immuno-staining of Whole Bone Marrow Cells
Wild-type, ASC-mCitine Tg or ASC-mCherry knock in reporter mice were anesthetized with isoflurane and sacrificed by cervical
dislocation. Femurs and tibias from hind limbs were removed and the bones were briefly disinfected with 70% ethanol. The bone
marrow cavity was flushed with PBS and the cell suspension was filtered through a 70 mm cell strainer before centrifugation
(400 x g, 5 minutes). Cells were resuspended in staining buffer and blocked with 1:10 mouse FcR blocking reagent for 10 minutes
at RT before staining with fluorochrome-conjugated anti-mouse CD41 (platelet marker), Ly6G (neutrophil marker), CD14 (monocyte
marker) or CD45 (leukocyte marker) (1:5 dilution each). Staining was performed for 30 min at room temperature. Cells were washed
twice in PBS and resuspended in staining buffer before flow cytometry analysis or confocal microscopy imaging. Compensation
beads (OneComp eBeads) and isotype controls were prepared in the same way. Flow cytometry was performed on MacsQuant
VYB and analyzed using FlowJo. The gating strategy was based on doublet discrimination and isotype-matched control antibodies
or unstained controls.
Generation of Platelet and MK supernatants
After platelet isolation, the cell suspension was adjusted to 5x107 platelets ml-1 (for human experiments) or 5x106 platelets ml-1 (for
mouse BMDM experiments), in order to fit the macrophage:platelets proportion of 1:50 (human) or 1:5 (mouse). For the generation of
supernatants from the megakaryocytic cell line MEG-01, 1x106 cells ml-1 were used. Next, platelets or MEG-01 were left untreated
(Unstim) or incubated at 37Cwith LPS (200 ngml-1) or thrombin (1.0 Uml-1) for 3 hours. After stimulation, the platelet cell suspension
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was centrifuged for 10 minutes at 3000 x g for the generation of the cell-free supernatants. MEG-01 cells were first centrifuged for
7 minutes at 170 x g and the obtained supernatants were centrifuged again for 10 minutes at 3000 x g. The absence of cells was
confirmed by microscopic visualization in a hemocytometer. The supernatants were immediately used to stimulate hMDMs in
RPMI, or immediately frozen at 80C until further use.
Stimulation of THP-1 and MEG-01 cells
For stimulation assays, THP-1 cells were treated overnight with 100 nM phorbol 12-myristate 13-acetate, then were primed for 2 h
with 1 mg ml-1 of LPS and were subsequently activated with 10 mM of Nigericin.
Stimulation assays
Seeded BMDMs, human macrophages or neutrophils were centrifuged at 350 x g for 5 minutes prior to replacing the supernatant by
fresh, serum-free DMEM (for BMDMs) or RPMI (for human neutrophils and macrophages) as control or platelet suspension. For
NLRP3 stimulation, cells were primedwith 200 ngml-1 LPS for 3 hours and activatedwith 10 mMNigericin or 5mMATP for 90minutes
unless otherwise indicated. Human monocytes were primed with 2 ng ml-1 of LPS before being activated with Nigericin (10 mM,
90 min).
For the stimulation of the NLRC4 inflammasome, human macrophages were primed with 200 ng ml-1 LPS for 3 hours before
2 mg ml-1 LFn-PrgI and 0.5 mg ml-1 PA (from Bacillus anthracis) were added to the culture medium for 2 hours (Zhao et al., 2011).
For the stimulation of the AIM2 inflammasome, humanGM-CSF-derivedmacrophageswere primedwith LPS (200 ngml-1, 3 hours),
followed by stimulation with transfected Poly(dA:dT). Briefly, vesicles were formed using a 1:50 dilution of the transfection agent Lip-
ofectamine 2000 in OptiMEM. After 15 minutes of incubation, the empty vesicles were combined in 1:1 proportion of 4 mg ml-1
Poly(dA:dT), and further incubated for 15 minutes. The dsDNA-containing vesicles were added directly on the cell culture for a final
volume of 100 ml of medium (final stimulatory concentration of 1 mg ml-1). Cells were stimulated for 3 hours before cell-free superna-
tants were harvested for cytokine measurements.
R848 and Pam3Cysk4 were also used for priming in some experiments at 10 mMand 1 mg ml-1 respectively. After stimulation, cells
were centrifuged and cell-free supernatants were collected to measure cytokine levels by HTRF. In experiments where the activity of
COX1/2 and LOX was inhibited, platelets were incubated with Aspirin, or Zileuton (both at 100 mM) for 60 min at 37C, before their
addition to hMDMs. SB-431542 (10 mM)was added to themacrophage culture 60minutes before stimulation. The drugs were diluted
in RPMI 1640, without supplements.
Trans-well assays
HMDMswere seeded at a concentration of 13 105/100 mL in HTS 0.4 mmTrans-well 96-well plates on the day prior to the experiment.
Platelets were added to the upper wells at a concentration of 6.253 107 in 80 mL of DMEM. After addition of platelets, inflammasome
activation was carried out as described above and the levels of IL-1b and TNFa were assessed in cell-free supernatants by HTRF.
Calcium chelation experiments
The calcium chelator BAPTA or the cell-permeable calcium chelator BAPTA-AM (see STAR Methods) were used to examine extra-
cellular and intracellular calcium involvement respectively. hMDMs were seeded in RPMI medium (for BAPTA-AM treatment) or in
calcium-free medium (for BAPTA treatment) with or without platelets as described before. Cells were primed with 200 ng ml-1
LPS for 3 hours before the addition of either 0.5 mM BAPTA or 5 mM BAPTA -AM. Then, cells were stimulated with 10 mM Nigericin
for NLRP3 Inflammasome activation. Cell-free supernatants were analyzed afterward by HTRF for cytokine secretion.
Quantitative PCR
Total RNA containing small RNAs from purified human platelets, or PBMCs was purified using the miRNeasy kit (QIAGEN), DNA was
digested with DNase I (QIAGEN), and cDNA was generated by using 500 ng RNA with SuperScript III Reverse Transcriptase kit
(Thermo Fisher) following the manufacturer’s instructions. cDNA was diluted (1:10 for PBMCs, and 1:3 for platelets) and qPCR
was performed with Maxima SYBR Green on a QuantStudio 6 Flex RT PCR machine (Thermo Fisher) for 40 cycles and followed
by a melt curve analysis for off-target products. The primers used were ACTB-fwd-ccaccatgtaccctggcatt, ACTB-rev-cggag
tacttgcgctcagga, NLRP3-fwd-tcggagacaaggggatcaaa, NLRP3-rev-agcagcagtgtgacgtgagg, CD14-fwd-gagctcagaggttcggaaga,
CD14-rev-cttcatcgtccagctcacaa, PYCARD-fwd-gagctcaccgctaacgtgct, PYCARD-rev-actgaggaggggcctggat, PF4-fwd-ctgaagaa
gatggggacctg, PF4-rev-gtggctatcagttgggcagt, CASP1-fwd-acaacccagctatgcccaca, CASP1-rev-gtgcggcttgacttgtccat, GP1BA-
fwd-ctgctctttgcctctgtggt, GP1BA-rev-ctccaggtgtgtggtttgtg, IL1B-fwd-tgggcagactcaaattccagct, IL1B-rev-ctgtacctgtcctgcgtgttga.
Imaging and quantification of ASC specks
To examine ASC specking, hMDMs were seeded at a concentration of 23 105/well in 8-well IBIDI m-slide one day prior to the exper-
iment. Freshly isolated platelets were added to hMDMs on the day of the experiment at a concentration of 53 107 ml-1 . Cells were
stimulated with 200 ng ml-1 LPS for 3 hours and the NLRP3 inflammasome was activated with 10 mMNigericin for 45 minutes. After-
ward, the plate was centrifuged (500 x g, 5 minutes) and the cells were fixed with 4% paraformaldehyde in PBS for 10 minutes on ice.
After two washes with PBS, cells were blocked with 1:10 human FcR blocking reagent for 10 minutes at room temperature and
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stained with directly labeled anti-ASC-647 or the same amount of directly labeled IgG1 control and incubated overnight at 4C in the
dark (section 3.1.6). On the next day, cells werewashed twicewith permeabilization buffer (500 x g, 5minutes) before staining with the
DNA dye Hoechst (1:3000 dilution) in PBS for 10 minutes at RT in the dark. After two subsequent washes with PBS, cells were re-
suspended in PBS and imaged using an Observer.Z1 epifluorescence microscope, 20 3 objective (dry, PlanApochromat, NA 0.8;
ZEISS, Oberkochen, Germany), Axiocam 506mono, and ZEN Blue software (ZEISS, Oberkochen, Germany). Representative images
were taken using a Leica TCS SP5 SMD confocal system. The quantification of ASC specks per nuclei was carried out using the im-
age analyzer software CellProfiler 3.0 (Open source software: https://cellprofiler.org). A pipeline was constructed to convert the fluo-
rescent images into binary code. Through this conversion, the nuclei and ASC specks were identified and quantified. ASC specks
were identified using the EnhanceFeature tool.
Cytokine measurements
Levels of human, or murine IL-1b, IL-6, and TNFa in cell-free supernatants were quantified using commercially available HTRF
(homogeneous time-resolved fluorescence) kits. The HTRFwas performed according tomanufacturer instructions (Cisbio). Multiplex
Cytokine array was used for the detection of several human cytokines and growth factors according to the manufacturer’s instruc-
tions (Thermo Fisher).
Caspase-1 activity
Caspase-Glo 1 Inflammasome Assay (Promega) provides a luminogenic caspase-1 substrate, Z-WEHD-amino luciferin, in a lytic
reagent optimized for caspase-1 activity and luciferase activity. The reaction buffer was mixed with the cell-free supernatant and the
luminescent signal was evaluated 30 minutes later.
Lactate dehydrogenase (LDH) assay
The extracellular lactate dehydrogenase (LDH) concentrations in cell-free supernatants were assessed using the Pierce LDH Cyto-
toxicity Assay, according to the manufacturer’s instructions. Samples were measured at an absorbance of 490 nm using a Spectra-
max i3 plate reader (ThermoFisher). Control hMDMs cultured at the same conditions as the samples were lysed with the provided
Lysis buffer (10x) and served as positive control for maximal LDH release.
Confocal laser scanning microscopy
Platelets and immune cells were imaged in a Leica TCS SP5 SMD confocal system (Leica Microsystems, Wetzlar, Germany). Images
were acquired using a 63X objective, with a numerical aperture of 1.2, and analyzed using the Volocity 6.01 software (PerkinElmer,
Waltham, Massachusetts, U.S.A.).
Meta-analysis of microarray data
Pre-processed microarray data of platelets and whole peripheral blood cells under steady state and certain disease states
(GSE2006, GSE11524, GSE10361, GSE50858, GSE47018, GSE17924) were down-loaded from the Gene Expression Omnibus
(GEO) data base (https://www.ncbi.nlm.nih.gov/geo/). Expression values for the house-keeping gene GAPDH and platelet- as
well as inflammasome-associated genes (CXCL4/PFA4, PDGFA, IL1B, PYCARD, NLRP3, TIMP1 CASP1, ARG2, TP2A, SELENB1)
were extracted for each dataset. In case multiple probe sets for GAPDH were present on the microarray chip, a mean expression
value for GAPDHwas calculated. The expression values for probe sets of platelet and inflammasome-associated geneswere normal-
ized for each dataset according to the respective GAPDH mean expression value. Log2 transformed normalized expression data
were plotted as bar charts by the Tidyverse package in R (v3.4.2).
Proteomics (LC-MS)
Suspensions of freshly isolated human platelets were adjusted to a concentration of 5x107ml-1 in RPMI. Platelets were left untreated,
or stimulated with 200 ngml-1 LPS, 1 Uml-1 Thrombin for 3 hours. Platelets were pelleted by centrifugation (3000 x g, 10minutes) and
the cell-free supernatants were harvested. Cell-free supernatants were added with 1x complete protease inhibitor cocktail prior to
freezing at 80C. Proteomics analysis was carried out at the CECAD/CMMC Proteomics Core Facility (University Cologne, Ger-
many) on a Q Exactive Plus Orbitrap (Thermo Scientific) mass spectrometer that was coupled to an EASY-nLC (Thermo Scientific).
Briefly, peptides were loaded in 0.1% formic acid in water onto an in-house packed analytical column (50 cm o´ 75 mm I.D., filled with
2.7 mm Poroshell EC120 C18, Agilent) and were chromatographically separated at a constant flow rate of 250 nl/minute with the
following gradient: 3%–4% solvent B (0.1% formic acid in 80 % acetonitrile) within 1 minute, 4%–27% solvent B within 119 minute,
27%–50% solvent B within 19 minutes, 50%–95% solvent B within 1 minutes, followed by washing and equilibration of the columns.
The mass spectrometer was operated in data-dependent acquisition mode. All mass spectrometric raw data were processed by the
CECAD/CMMC Proteomics Core Facility using Maxquant (version 1.5.3.8) with default parameters. Briefly, MS2 spectra were
analyzed against the Uniprot HUMAN. fasta (downloaded at: 16.6.2017) database, including a list of common contaminants. False
discovery rates on protein and PSM level were estimated by the target-decoy approach to 1% FDR for both. The minimal peptide
length was determined to be 7 amino acids and carbamidomethylation at cysteine residues was considered as a fixed modification.
Oxidation and acetylation were included as variable modifications. For the analysis, the match-between runs option was enabled.
e9 Cell Reports 31, 107615, May 12, 2020
Article
ll
OPEN ACCESS
Label-free quantification (LFQ) was activated using default settings. Figures were assembled using the R Tidyverse package. The
mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [1] partner repository
with the dataset identifier PXD017976.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed with GraphPad Prism Version 7.0f. All statistical analysis were preceded by Normality tests, fol-
lowed by the recommended parametric or nonparametric tests. For most in vitro experiments with several groups (hMDMs alone
versus with Platelets, stimulated or not), P values were determined by two-way ANOVA with Tukey’s or Sidak’s or multiple compar-
ison tests. For in vivo experiments, in which two groups of mice are compared (n = 6/group), (Figure 3) we used two-tailed Unpaired t
test to calculate differences. Correlations between cytokines and cell counts were computed with Two-tail Spearman. Outliers were
detected using the ROUT method, and were excluded from the statistical analysis, but not removed from the figures. Additional sta-
tistical details are given in the respective figure legends, when appropriate.
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